NCT02328014: A reported trial by Acerta Pharma BV
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02328014 |
|---|---|
| Title | A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 20, 2014 |
| Completion date | June 1, 2020 |
| Required reporting date | June 1, 2021, midnight |
| Actual reporting date | May 21, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |